Home
Nabriva Therapeutics plc

Nabriva Therapeutics plc Market Share Analysis for June 2026

Nabriva Therapeutics is a commercial-stage biopharmaceutical company engaged in the development of innovative anti-infective agents to treat serious infections.

Health > Biotechnology and Pharmaceuticals

Domainnabriva.com

Year Founded2006

Employees51 - 200

Annual Revenue$25M - $50M

Nabriva Therapeutics plc

Nabriva Therapeutics plc (including company regionals)

nabriva.com

See more website traffic and engagement information

Nabriva Therapeutics plc Revenue up to June 2026 is 25M - 50M

revenue generated by Nabriva Therapeutics plc top domains

Nabriva Therapeutics plc top domains revenue over 3 years

Revenue for Nabriva Therapeutics plc top domains

nabriva.com25M - 50M

See more with Sales Intelligence

Total visits to Nabriva Therapeutics plc's top domains

Understand Nabriva Therapeutics plc market share and potential market reach.

Total visits last 3 months

No Data to Display

Avg. visit duration in Nabriva Therapeutics plc's top domains

Analyze Nabriva Therapeutics plc engagement metrics.

Average visit duration last 3 months

No Data to Display

Avg. pageviews on Nabriva Therapeutics plc's top domains

See how Nabriva Therapeutics plc keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

No Data to Display

Nabriva Therapeutics plc top competitors by domain

Top similar sites in June 2026, ranked by their affinity

flenpharma.comCompany NameFlen PharmaEmployees51 - 200HQNetherlands, ArnhemAnnual revenue$25M - $50MTotal visits--Health > Biotechnology and Pharmaceuticals

Top technologies used by Nabriva Therapeutics plc

These are the website technologies, by industry, used by Nabriva Therapeutics plc top domains

Conversion & Analytics (5)

Google Analytics

Content Management System (3)

WordPress

Mobile (3)

Meta Viewport

Social (2)

Instagram

More Technologies

7

See all

News & Signals from Nabriva Therapeutics plc

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsNabriva Therapeutics plc sold assets to Meitheal Pharmaceuticals, Inc. on Jul 18th '24.Meitheal acquires North American rights to Contepo from Nabriva.

NewsNabriva Therapeutics plc sold assets to Sumitomo Pharma Co., Ltd on Jul 1st '23.Subsequently, in July 2023, Sumitomo Pharma acquired the asset of XENLETA(R) in Chinese mainland, Taiwan, Hong Kong, and Macau from Nabriva Therapeutics.

NewsNabriva Therapeutics plc partnered with Erkim Ilac on Jul 18th '22.Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it has entered into an exclusive Distribution Agreement with Er-Kim, a leading partner for biotech companies in international markets, for the oral and intravenous formulations of XENLETA ® (lefamulin).